Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.

@article{Ozbek2009DisappearanceOA,
  title={Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.},
  author={M. Ozbek and M. Erdoğan and E. Akbal and G{\"u}ls{\"u}m G{\"o}n{\"u}lalan},
  journal={Experimental and clinical endocrinology \& diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association},
  year={2009},
  volume={117 7},
  pages={
          309-11
        }
}
  • M. Ozbek, M. Erdoğan, +1 author Gülsüm Gönülalan
  • Published 2009
  • Medicine
  • Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Acromegaly is caused by excessive growth hormone secretion, usually from a pituitary adenoma. Increased mortality rate is reverted to that of the normal population after decreasing GH and IGF-I levels to less than 2-2.5 microg/liter and normal sex- and age-matched controls, respectively, regardless of the treatment employed. The use of somatostatin analogues as primary or adjunctive therapy has been widely applied in the management of acromegaly. A few cases have been reported in the literature… Expand
The place of medical treatment of acromegaly: current status and perspectives
Diagnosis, treatment and clinical perspectives of acromegaly
Medical therapy of acromegaly in Turkey
Expert consensus document: A consensus on the medical treatment of acromegaly
Immune modulation in humans: implications for type 1 diabetes mellitus

References

SHOWING 1-10 OF 31 REFERENCES
Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Growth-hormone and prolactin excess
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
...
1
2
3
4
...